Anistreplase (Anisoylated Plasminogen Streptokinase Activator Complex, Apsac) in Coronary Thrombolysis
Anistreplase was introduced and developed as a thrombolytic agent for two reasons: first, the hope that it would act as a fibrin-selective agent and reduce the risks of hemorrhage associated with streptokinase; second, its pharmacokinetic properties, which allow it to be given as a single injection rather than an infusion. The first aspiration has not been fulfilled. The second property has, however, been very useful, particularly for prehospital fibrinolysis.
KeywordsAcute Myocardial Infarction ANISOYLATED Plasminogen Streptokinase Activator Complex Acute Myocar Intracoronary Streptokinase Coronary Thrombolysis
Unable to display preview. Download preview PDF.
- 7.AIMS Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 2:545, 1988.Google Scholar
- 9.ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 39:753, 1992.Google Scholar
- 13.Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 24:1602, 1994.PubMedGoogle Scholar
- 15.O’Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streprokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 23:11, 1994.PubMedGoogle Scholar
- 16.Julian DG. Aspirin or anticoagulants after thrombolysis with anistreplase: Preliminary data from the AFTER study. Eur Heart J 13 (Abstract Suppl.): 307, 1992.Google Scholar
- 17.Vanderscheuren S, Barrios L, Kerdsinchai P, Van der Heuvel P, Hermans L, Vrolix M, et al. A randomised trial of recombinant staphylokinase versus alteplase for coronary artery patency in myocardial infarction. Circulation 92:2044, 1995.Google Scholar